Trial Profile

A 24-week Open-label, Non-interventional Study of the Efficacy and Safety of Olokizumab Therapy in Patients with Rheumatoid Arthritis After Switching from Anti-B-cell Therapy During the SARS-COV-2 Pandemic

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 02 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 Jan 2024 New trial record
15 Nov 2023 Results assessing efficacy and safety of olokizumab, solution, presented at the ACR Convergence 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com